moxidectin + diethylcarbamazine + albendazole

The combination of moxidectin, diethylcarbamazine, and albendazole is an antiparasitic treatment regimen being evaluated for lymphatic filariasis (LF). This combination has been studied in clinical trials to determine its efficacy, safety, and pharmacokinetic interactions compared to standard treatments containing ivermectin[1][3]. ## Mechanism of Action Each component in this combination has a specific antiparasitic mechanism: - **Moxidectin**: A milbemycin endectocide similar to ivermectin that was approved by the U.S. FDA in 2018 for treating onchocerciasis in persons at least 12 years of age. It provides prolonged clearance of microfilariae from the skin[1][2][3]. - **Diethylcarbamazine**: Works by disrupting parasite mobility and metabolism by opening Transient Receptor Potential (TRP) channels in parasite muscle, causing temporary spastic paralysis. This makes the parasites easier for the immune system to eliminate[7][10]. - **Albendazole**: Prevents worms from absorbing sugar (glucose), causing them to lose energy and die[6]. ## Clinical Research The combination has been studied in clinical trials, particularly by the Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project team from Washington University in St. Louis. Study NCT04410406 evaluated the safety, efficacy, and pharmacokinetics of this combination compared to ivermectin-based treatments[5]. Research has shown that a single dose of moxidectin 8 mg in combination with albendazole 400 mg (with or without diethylcarbamazine 6 mg/kg) was more effective than ivermectin 200 μg/kg plus albendazole 400 mg (IA) and at least as effective as the triple combination of ivermectin, diethylcarbamazine, and albendazole (IDA) for clearing Wuchereria bancrofti microfilariae[5]. ## Safety Profile The safety profile of this combination has been found to be comparable to standard ivermectin-containing regimens. Treatment-emergent adverse events (TEAEs) are generally mild to moderate and similar to those seen with current WHO-recommended treatments[8]. The addition of moxidectin to the combination did not alter the drug exposure of co-administered drugs, suggesting no clinically significant pharmacokinetic interactions[1][2][3]. This combination represents a potential advancement in mass drug administration (MDA) programs for lymphatic filariasis elimination, offering possibly improved efficacy with a safety profile similar to existing treatments.